Disclosure of the July 2026 monthly exercise status for the docirbrutinib (AS-1763) development-accelerating stock option. Shares issued: 40,000 shares; rights exercised: 400 (0.51% of issued shares). Unexercised rights at month-end: 7,570,300 shares. Exercise restriction ratio: 0.20%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4572","jir_company_name":"\u30ab\u30eb\u30ca\u30d0\u30a4\u30aa\u30b5\u30a4\u30a8\u30f3\u30b9\u682a\u5f0f\u4f1a\u793e","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4572-20260803-01.pdf","jir_short_summary":"Disclosure of the July 2026 monthly exercise status for the docirbrutinib (AS-1763) development-accelerating stock option. Shares issued: 40,000 shares; rights exercised: 400 (0.51% of issued shares). Unexercised rights at month-end: 7,570,300 shares. Exercise restriction ratio: 0.20%.","jir_summary":"### Overview\nCurna Bioventures (\u30ab\u30eb\u30ca\u30d0\u30a4\u30aa\u30b5\u30a4\u30a8\u30f3\u30b9) discloses the July 2026 monthly exercise status for the docirbrutinib (AS-1763) stock option. Issued shares: 40,000; exercised rights: 400 (0.51% of issued shares); unexercised rights at month-end: 7,570,300. Exercise restriction ratio is 0.20%, indicating limited exercise in the target month.\n\n### Outlook & Impact\nExercise activity for stock options is limited, and dilution impact is expected to be small. Reference to related information from past disclosures is recommended, and additional disclosures may be considered depending on future exercise status.","jir_financial_highlights":"Issued shares: 40,000 shares (Unknown)\nNumber of stock options exercised: 400 rights (YoY unknown)\nExercise rate against issued shares: 0.51% (Unknown)","jir_category":"","jir_hashtags":"#KarnaBiotherapeutics, #stock_option, #JapanEquities","jir_key_figures":"Issued shares: 40,000 shares\nNumber of stock options exercised: 400 rights\nExercise rate against issued shares: 0.51%","jir_meta_title":"\u3010Karna Biotherapeutics\u3011 Monthly exercise status of stock options disclosed \uff5c July 2026","jir_meta_description":"Karna Biotherapeutics announces the monthly exercise status of docirbrutinib (AS-1763) development-accelerating stock options. Details include 40,000 issued shares, 400 exercised rights, 7,570,300 unexercised shares, and more.","jir_og_title":"Karna Biotherapeutics \uff5c Monthly stock option exercise status (2026\/7)","jir_og_description":"Discloses July exercise status for docirbrutinib stock options. Issued shares 40,000; exercised 400; unexercised 7,570,300; exercise ratio 0.20% within the limit.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59427,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-93831","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n